FMP
Advicenne S.A.
ADVIC.PA
EURONEXT
Inactive Equity
Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.
6.5 EUR
0 (0%)
About
ceo
Dr. Andr Ulmann M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.advicenne.com
exchange
EURONEXT
Description
Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.
CIK
N/A
ISIN
FR0013296746
CUSIP
F01097108
Address
2 Rue Briconnet
Phone
33466055420
Country
FR
Employee
32
IPO Date
Dec 6, 2017
Summary
CIK
-
Exchange
EURONEXT
Industry
Biotechnology
Sector
Healthcare
CUSIP
F01097108
ISIN
FR0013296746
Country
FR
Price
6.5
Beta
1.43
Volume Avg.
45.76k
Market Cap
0
Shares
-
52-Week
6.07-6.62
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.67
P/B
-
Website
https://www.advicenne.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ADVIC.PA News
It looks like there's no news available.
